212 related articles for article (PubMed ID: 19878763)
21. Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
Almalki MH; Aljoaib NN; Alotaibi MJ; Aldabas BS; Wahedi TS; Ahmad MM; Alshahrani F
Hormones (Athens); 2017 Apr; 16(2):139-149. PubMed ID: 28742502
[TBL] [Abstract][Full Text] [Related]
22. Refractory pituitary adenoma: a novel classification for pituitary tumors.
Dai C; Feng M; Liu X; Ma S; Sun B; Bao X; Yao Y; Deng K; Wang Y; Xing B; Lian W; Zhong D; Ma W; Wang R
Oncotarget; 2016 Dec; 7(50):83657-83668. PubMed ID: 27845901
[TBL] [Abstract][Full Text] [Related]
23. [Aggressive pituitary adenoma and pituitary carcinoma].
Tóth M
Orv Hetil; 2023 Jul; 164(30):1167-1175. PubMed ID: 37516994
[TBL] [Abstract][Full Text] [Related]
24. [Pituitary adenomas--where is the treatment heading at the beginning of the 21st century?].
Marek J
Vnitr Lek; 2010 Jul; 56(7):690-4. PubMed ID: 20842914
[TBL] [Abstract][Full Text] [Related]
25. O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.
Salehi F; Scheithauer BW; Kovacs K; Horvath E; Syro LV; Sharma S; Manoranjan B; Cusimano M
Neurosurgery; 2012 Feb; 70(2):491-6; discussion 496. PubMed ID: 21822153
[TBL] [Abstract][Full Text] [Related]
26. Metastatic prolactinoma: case report with immunohistochemical assessment for p53 and Ki-67 antigens.
Crusius PS; Forcelini CM; Mallmann AB; Silveira DA; Lersch E; Seibert CA; Crusius MU; Carazzo CA; Crusius CU; Goellner E
Arq Neuropsiquiatr; 2005 Sep; 63(3B):864-9. PubMed ID: 16258673
[TBL] [Abstract][Full Text] [Related]
27. Management of nonfunctioning pituitary adenomas.
Sassolas G; Trouillas J; Treluyer C; Perrin G
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():21-6. PubMed ID: 8103955
[TBL] [Abstract][Full Text] [Related]
28. Pituitary carcinoma - case series and review of the literature.
Du Four S; Van Der Veken J; Duerinck J; Vermeulen E; Andreescu CE; Bruneau M; Neyns B; Velthoven V; Velkeniers B
Front Endocrinol (Lausanne); 2022; 13():968692. PubMed ID: 36157469
[TBL] [Abstract][Full Text] [Related]
29. Multimodality treatment for invasive pituitary adenomas.
Hornyak M; Couldwell WT
Postgrad Med; 2009 Mar; 121(2):168-76. PubMed ID: 19332975
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
31. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.
Raverot G; Burman P; McCormack A; Heaney A; Petersenn S; Popovic V; Trouillas J; Dekkers OM;
Eur J Endocrinol; 2018 Jan; 178(1):G1-G24. PubMed ID: 29046323
[TBL] [Abstract][Full Text] [Related]
32. Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.
Cuny T; Barlier A; Feelders R; Weryha G; Hofland LJ; Ferone D; Gatto F
Ann Endocrinol (Paris); 2015 Feb; 76(1):43-58. PubMed ID: 25556152
[TBL] [Abstract][Full Text] [Related]
33. Thyrotropin-secreting pituitary adenomas: biological and molecular features, diagnosis and therapy.
Losa M; Fortunato M; Molteni L; Peretti E; Mortini P
Minerva Endocrinol; 2008 Dec; 33(4):329-40. PubMed ID: 18923369
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study.
Daly AF; Tichomirowa MA; Petrossians P; Heliövaara E; Jaffrain-Rea ML; Barlier A; Naves LA; Ebeling T; Karhu A; Raappana A; Cazabat L; De Menis E; Montañana CF; Raverot G; Weil RJ; Sane T; Maiter D; Neggers S; Yaneva M; Tabarin A; Verrua E; Eloranta E; Murat A; Vierimaa O; Salmela PI; Emy P; Toledo RA; Sabaté MI; Villa C; Popelier M; Salvatori R; Jennings J; Longás AF; Labarta Aizpún JI; Georgitsi M; Paschke R; Ronchi C; Valimaki M; Saloranta C; De Herder W; Cozzi R; Guitelman M; Magri F; Lagonigro MS; Halaby G; Corman V; Hagelstein MT; Vanbellinghen JF; Barra GB; Gimenez-Roqueplo AP; Cameron FJ; Borson-Chazot F; Holdaway I; Toledo SP; Stalla GK; Spada A; Zacharieva S; Bertherat J; Brue T; Bours V; Chanson P; Aaltonen LA; Beckers A
J Clin Endocrinol Metab; 2010 Nov; 95(11):E373-83. PubMed ID: 20685857
[TBL] [Abstract][Full Text] [Related]
35. Management of aggressive pituitary adenomas: current treatment strategies.
Buchfelder M
Pituitary; 2009; 12(3):256-60. PubMed ID: 19003540
[TBL] [Abstract][Full Text] [Related]
36. Radiotherapy of pituitary adenomas: state of the art.
Gilliot O; Khalil T; Irthum B; Zasadny X; Verrelle P; Tauveron I; Pontvert D
Ann Endocrinol (Paris); 2007 Oct; 68(5):337-48. PubMed ID: 17512895
[TBL] [Abstract][Full Text] [Related]
37. Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management.
Zemmoura I; Wierinckx A; Vasiljevic A; Jan M; Trouillas J; François P
Pituitary; 2013 Dec; 16(4):515-22. PubMed ID: 23184261
[TBL] [Abstract][Full Text] [Related]
38. Atypical pituitary adenomas: incidence, clinical characteristics, and implications.
Zada G; Woodmansee WW; Ramkissoon S; Amadio J; Nose V; Laws ER
J Neurosurg; 2011 Feb; 114(2):336-44. PubMed ID: 20868211
[TBL] [Abstract][Full Text] [Related]
39. Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor.
Lin AL; Donoghue MTA; Wardlaw SL; Yang TJ; Bodei L; Tabar V; Geer EB
J Clin Endocrinol Metab; 2020 Dec; 105(12):3807-20. PubMed ID: 32930787
[TBL] [Abstract][Full Text] [Related]
40. Non-functioning pituitary adenomas.
Chanson P; Brochier S
J Endocrinol Invest; 2005; 28(11 Suppl International):93-9. PubMed ID: 16625856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
